Claims for Patent: 10,960,004

Summary for Patent: 10,960,004

Title:	Method for treating cancer patients with severe renal impairment
Abstract:	A method for treating cancer in patients with creatinine clearance of 15 mL/min or more and less than 30 mL/min, including dividing a combination drug containing .alpha.,.alpha.,.alpha.-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a dose of 30 to 50 mg/m.sup.2/day as FTD-equivalent, into two to four times a day, and orally administering it to the patient.
Inventor(s):	Yoshida; Kenichiro (Tsukuba, JP)
Assignee:	TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP)
Application Number:	16/574,180
Patent Claims:	1. A method for treating gastrointestinal cancer, large bowel cancer or breast cancer in a patient with a creatinine clearance of 15 mL/min-29 mL/min, comprising: orally administering a drug comprising .alpha.,.alpha.,.alpha.-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, at a daily dose of 30 to 40 mg/m.sup.2/day as FTD-equivalent, in two to four doses a day to the patient with a creatinine clearance of 15 mL/min-29 mL/min. 2. The method of claim 1, wherein a dose of 40 mg/m.sup.2/day as FTD-equivalent is administered in two doses a day. 3. The method of claim 1, wherein an administration schedule is 5-day consecutive oral administrations and 2-day rest, per week. 4. The method of claim 1, wherein an administration schedule of 5-day consecutive oral administrations and 2-day rest is repeated twice, followed by rest for 14 days. 5. The method of claim 1, wherein gastrointestinal cancer or breast cancer is treated. 6. The method of claim 1, wherein large bowel cancer is treated. 7. The method of claim 6, wherein colorectal cancer is treated. 8. The method of claim 5, wherein at least one of gastric cancer and esophageal cancer is treated. 9. The method of claim 5, wherein breast cancer is treated. 10. The method of claim 1, wherein a dose of 30 mg/m.sup.2/day as FTD-equivalent is administered in two doses. 11. The method of claim 10, wherein an administration schedule is 5-day consecutive oral administrations and 2-day rest, per week. 12. The method of claim 10, wherein an administration schedule of 5-day consecutive oral administrations and 2-day rest is repeated twice, followed by rest for 14 days. 13. The method of claim 10, wherein gastrointestinal cancer or breast cancer is treated. 14. The method of claim 10, wherein colorectal cancer is treated. 15. The method of claim 10, wherein at least one of gastric cancer and esophageal cancer is treated. 16. The method of claim 10, wherein breast cancer is treated. 17. The method of claim 2, wherein an administration schedule is 5-day consecutive oral administrations and 2-day rest, per week. 18. The method of claim 2, wherein an administration schedule of 5-day consecutive oral administrations and 2-day rest is repeated twice, followed by rest for 14 days. 19. The method of claim 2, wherein gastrointestinal cancer or breast cancer is treated. 20. The method of claim 2, wherein colorectal cancer is treated. 21. The method of claim 2, wherein at least one of gastric cancer and esophageal cancer is treated. 22. The method of claim 2, wherein breast cancer is treated. 23. The method of claim 3, wherein gastrointestinal cancer or breast cancer is treated. 24. The method of claim 3, wherein colorectal cancer is treated. 25. The method of claim 3, wherein at least one of gastric cancer and esophageal cancer is treated. 26. The method of claim 3, wherein breast cancer is treated. 27. The method of claim 4, wherein gastrointestinal cancer or breast cancer is treated. 28. The method of claim 4, wherein colorectal cancer is treated. 29. The method of claim 4, wherein at least one of gastric cancer and esophageal cancer is treated. 30. The method of claim 4, wherein breast cancer is treated.